Form 4: Collegium CFO Sells 30,000 Shares Under 10b5-1 Plan

Collegium Pharmaceutical's EVP & CFO, Colleen Tupper, sold 30,000 shares of common stock on November 6, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Colleen Tupper, Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical, Inc. (COLL), sold a total of 30,000 shares of the company's common stock.
• The transactions occurred on November 6, 2025.
• These sales were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on May 30, 2025.
• The shares were sold in two separate transactions: 25,142 shares at a weighted average price of $40.3801 (ranging from $40.00 to $40.98) and 4,858 shares at a weighted average price of $41.2756 (ranging from $41.00 to $41.75).
• Following these reported sales, Colleen Tupper beneficially owns 126,667 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 4

Explanation: While the sale is under a 10b5-1 plan, which mitigates some negative sentiment, the sale of a significant number of shares by a key executive (CFO) can still be perceived as a slight negative signal by the market, indicating a potential lack of strong upside conviction or simply personal diversification.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment for personal financial management rather than a reaction to immediate company news or a lack of confidence.

Negatives

• A key executive, the EVP & Chief Financial Officer, sold a significant number of shares (30,000 shares), which can sometimes be perceived negatively by the market.

Risks

• Insider selling, even when executed under a 10b5-1 plan, can occasionally be interpreted by investors as a signal that the executive believes the stock's near-term upside may be limited, potentially leading to negative market sentiment.

Future Outlook

This Form 4 filing is a transactional report and does not contain any specific forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider selling, particularly under a Rule 10b5-1 plan, is a common practice across various industries for executives to manage personal wealth, diversify portfolios, and address liquidity needs. It generally does not reflect specific industry trends unless there is a broader pattern of executive divestment across the sector.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for executive stock sales is a standard corporate governance practice, widely adopted by public companies to allow insiders to sell shares in a pre-arranged, transparent manner, mitigating concerns about trading on material non-public information.
• The volume of shares sold (30,000) represents a portion of the CFO's total holdings, which is a typical approach for executives managing their equity exposure and personal financial planning.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially leading to short-term price pressure, though the 10b5-1 plan mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The sale by the CFO, while significant, was conducted under a pre-arranged 10b5-1 plan, which suggests personal financial planning rather than a reaction to adverse company-specific news. This mitigates the negative signal typically associated with insider selling. Without additional information on the company's fundamentals or broader market conditions, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future developments.

Keywords

Collegium Pharmaceutical, COLL, Form 4, Insider Selling, Colleen Tupper, CFO, 10b5-1 Plan, Stock Sale, Executive Compensation